Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study

Risk of hospitalization and mortality remain high in patients with PAH. In particular, patients who are parenteral-naive at initiation of RTS-Epo therapy, male patients, and patients with CRI require close monitoring and aggressive clinical management.